Palobiofarma has completed the dose escalation of the Phase I clinical trial evaluating the safety and tolerability of the novel PDE10/A2a dual antagonist PBF-999 in patients with solid tumors. The trial has been conducted at the Vall D Hebron Hospital, in Barcelona, Spain. The product has demonstrated to be safe and well tolerated at all the doses treated, with stabilization of the disease seen in several patients. The corresponding dose expansion Phase in three selected tumor types is in progress.
Palobiofarma completed the dose escalation part of the Phase I study with PBF-999 in cancer patients
Recent News
- Palobiofarma Presents Phase 2 Results for Investigational PBF-999 in Prader-Willi Syndrome
- Palobiofarma announces significant advances in the clinical development of PBF-999 for Prader-Willi Syndrome
- Palobiofarma announce several important milestones dealing with the clinical development of PBF-999 for Prader-Willi Syndrome
- Palobiofarma Announces Completion of Dual A2A/H3 Receptor Antagonist Research Project for Parkinson’s Disease
- Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain